Portfolio company, Lucid Scientific, announced the closing of a $7M Series A financing led by IAG Capital Partners. Additional participants include Lucid’s original investor base, the Georgia Research Alliance’s Venture Fund, and Dynamk Capital.  The funds will be used to accelerate Lucid’s business, expanding its sales and marketing team, as well as product development. Lucid is reshaping drug discovery with their Resipher platform, a handheld device for real-time cellular analysis.